ArticleMedicine2026
Iron status modulates immune cell proportions to drive epigenetic age acceleration: A 2-step Mendelian randomization study.
Article in Medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Iron status is associated with human aging, but the underlying mechanisms are unclear. We aimed to estimate the causality of the association between iron status and human aging and to quantify the mediating effects of immune cells. Based on genome-wide association studies in European populations, we conducted a two-sample Mendelian randomization analysis to evaluate the causal relationships between 6 iron status biomarkers (iron, ferritin, transferrin saturation percentage, total iron-binding capacity, liver iron content, pancreatic iron content) and 5 types of percentage of immune cells (lymphocyte, neutrophil, monocyte, eosinophil, basophil). Next, we employed a 2-step Mendelian randomization design to investigate the potential role of immune cell proportions in mediating iron homeostasis-driven epigenetic aging. In this study, a 2-step randomization analysis demonstrated that lymphocyte percentage mediates 8.01% (mediation effect: 0.06; 95% confidence interval [CI]: 0.02 to 0.10) of ferritin's total effect on PhenoAge acceleration. Neutrophil percentage explained 4.88% (mediation effect: 0.03; 95% CI: 0.004 to 0.07) of the causal relationship between serum ferritin and PhenoAge acceleration, and 7.76% (mediation effect: 0.04; 95% CI: 0.01 to 0.07) of the causal relationship between transferrin saturation percentage and HannumAge acceleration. Lymphocyte and neutrophil proportions were found to partially mediate the causal association of iron status with epigenetic age acceleration. Interventions on changing the percentage of immune cells would be a potential strategy for regulating the pace of aging.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.